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Recent studies have shown that intestinal homeostasis may directly afect brain functioning, and consequently 
modulate afection, motivation and higher cognitive functions1–4. It has been proposed that microbes in the gut 
regulate brain processes through a bidirectional communication network known as the gut microbiota—brain 
axis (GBA)5–7. Communication in this axis occurs via three diferent pathways: neural (mainly by the vagus 
nerve and the enteric nervous system), endocrine (cortisol) and immune (cytokines)5–7. Several experimental 
approaches have been used to study the modulatory efects of gut microbiota on gut–brain interactions, includ-
ing gut microbial manipulation with antibiotics, faecal microbial transplantation and germ-free animal models 
(revised in Mayer et al.8). Overall, the results from these preclinical experiments suggest that the microbiota 
and its metabolites are likely involved in modulating behaviours and brain processes via the GBA, such as stress 
responsiveness, anxiety, depression and pain modulation8.
his emerging line of research has the potential to open new avenues in the treatment of disorders related to 
brain dysfunction3. One such new development is the use of probiotics. A probiotic preparation is a microorgan-
ism that beneicially afects the health of the host organism when ingested in an adequate dose9. Probiotic con-
sumption appears to exert a myriad of beneicial efects, including enhancement of immune response, balancing 
of colonic microbiota or reduction of faecal enzymes implicated in cancer initiation, among others10. In a recent 
review, the term psychobiotics was coined to describe the beneicial efects of probiotics in patients sufering 
from psychiatric illnesses11. However, this is a very new ield, and there is currently little evidence in support of 
the hypothesis that cognitive and emotional processes can be inluenced by probiotics via the GBA12,13. In one 
of the few double-blind placebo-controlled studies testing the efect of probiotics on mood, results showed that 
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a daily intake of a milk yogurt containing Lactobacillus casei Shirota during three weeks improved the mood of 
participants who had initially worse levels of mood14. Two other studies have also reported positive efects of pro-
biotics on anxiety and mood in healthy and moderately stressed human volunteers relative to a placebo-control 
group15,16. Interestingly, a recent study has shown that probiotics can improve depression, increase quality of life 
and reduce limbic activity to negative emotional stimuli in patients with irritable bowel syndrome17.
Recent accumulating evidence has suggested that probiotics, a non-invasive treatment with not known 
harmful side efects, could improve the physical, psychological and cognitive state of clinical populations with 
altered microbiota balance. One clinical population that its into this category are patients sufering from FMS18. 
Nowadays, FMS is deined as a chronic disorder characterised by widespread musculoskeletal pain accompanied 
by symptoms such as morning stifness, moderate or severe fatigue, depression, headaches and sleeping disor-
ders19–21. Emotional and mood problems are also common in FMS22–25. Another prevalent complaint is reduced 
mental performance26–31, being attention, episodic memory and working memory the cognitive domains that 
appear to be most frequently afected in this population29,32. hese deicits are mainly observed in complex tasks26, 
particularly those involving distraction or competition with other sources of information which tap on inhibitory 
mechanisms (e.g., Correa et al.33 and Leavitt and Katz34). FMS patients have also shown poor performance in 
tasks assessing abstraction, cognitive lexibility35 and decision-making35,36.
he aim of the present study was to test whether a multispecies probiotic could improve cognition, emotional 
symptoms and functional state in a population diagnosed with FMS. Regarding to cognition, we decided to focus 
on two impulsivity constructs (impulsive choice and decision-making) since previous research has suggested a 
link between impulsivity and FMS33,35. he two-choice task and the Iowa gambling task has been widely used in 
the literature to measure the construct of impulsive choice and emotion-based decision-making, respectively. 
Although this is a relatively new ield of research and there are few studies investigating the efect of probiotics on 
human cognition, based on the evidence discussed above, we hypothesised that FMS patients would show better 
performance on these two tasks ater the treatment with probiotics. We also expected to observe a beneicial 
efect of the intervention on the emotional (e.g., depression and anxiety) and physiological measures (free cortisol 
concentration in urine).

ǡǤ Table 1 shows the participant charac-
teristics for each group (probiotic versus placebo). No signiicant group diferences were observed for gender 
distribution [χ2 (1, N = 31) = 0.44, p = 0.51], age [t(29) = 1.62, p = 0.12], time with FMS diagnosis [t(29) = 0.05, 
p = 0.96], years of formal education [t(29) = 0.30, p = 0.76], and BMI [t(29) = −0.34, p = 0.73].
Table 2 shows a summary of pre- and post-intervention scores on VAS, FIQ, SF-36, BDI, STAI, and MMSE and 
the mean measures of cortisol free urine for the probiotic and placebo groups.
he total score of the pain evaluation (VAS scores) did not reveal any signiicant efects (ps > 0.05). Also, the 
ANOVAs showed that the main efect of Group and Time by Group interaction were not signiicant for any of 
the measures (FIQ, SF-36, BDI, STAI at both state and trait scales, and MMSE) (ps > 0.05) (see Table 2). Only 
a main efect of Time was observed for the total score of the FIQ [F(1, 29) = 10.05, p = 0.036, ηp2 = 0.257], BDI 
[F(1, 29) = 8.61, p = 0.006, ηp2 = 0.229] and the SF-36, both for the General Health total score [F(1, 29) = 5.20, 
p = 0.03, ηp2 = 0.152] and for the emotional role dimension total score [F(1, 29) = 4.51, p = 0.04, ηp2 = 0.135].
Finally, the results from the ANOVA performed on the cortisol free urine levels revealed a main efect of Time 
[F(1, 28) = 75.26, p = 0.000, ηp2 = 0.729]. However, the main efect of Group and the Time by Group interaction 
did not reach statistical signiicance (ps > 0.05).
Ǥ On the two-choice task (a measure of impulsive choice), the number of impulsive choices 
made by both groups was analysed. he repeated measures ANOVA showed a signiicant Group by Time inter-
action [F(1, 21) = 5.53, p = 0.029, ηp2 = 0.208]. he analysis of the interaction revealed that both groups showed 
a similar number of impulsive choices during the pre-intervention assessment (see Fig. 1). However, the probi-
otic group presented a signiicantly reduced number of impulsive choices ater the treatment [F(1, 21) = 7.24, 
p = 0.014, ηp2 = 0.256]. No other signiicant efect was observed.
Impulsive decision-making was assessed by the IGT. he repeated measures ANOVA revealed only a mar-
ginal efect of Time [F(1, 21) = 3.82, p = 0.064, ηp2 = 0.154]. Given that the IGT is a learning task, although 
the three-way interaction did not reach signiicance (p < 0.05), we also conducted separate repeated-measures 
ANOVAs for each block. Only the analysis of the last block of 20 trials showed a main signiicant efect of Time 
[F(1, 21) = 5.55, p = 0.028, ηp2 = 0.209] and a marginal Group × Time interaction [F(1, 21) = 3.71, p = 0.066, 
Demographic characteristics
Probiotic Placebo
Participants (Female:Male) 16 (15:1) 15 (13:2)
Age (years) 55.00 (2.09) 50.27 (2.03)
Time with Fibromyalgia (years) 8.56 (1.47) 8.47 (1.50)
Formal education (years) 12.75 (0.95) 12.27 (1.29)
BMI (kg/m2) 29.40 (1.64) 30.23 (1.63)
Table 1. Demographic characteristics in the Probiotic and Placebo groups. Mean scores and standard error of 
the means (in parentheses) are shown.
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ηp2 = 0.152]. he analysis of the interaction revealed a signiicantly higher number of disadvantageous cards or 
impulsive choices made by the control group in the post-intervention phase as compared with the probiotic group 
[F(1, 21) = 5.20, p = 0.033, ηp2 = 0.198]. his was mainly due to the control group being more impulsive ater 
the treatment with the placebo substance [F(1, 10) = 10.52, p = 0.009, ηp2 = 0.513]. here were no diferences 
between both groups in the last block of trials of the pre-intervention phase (see Fig. 2).

he results obtained in the present pilot study showed that both groups, probiotics and placebo, signiicantly 
decreased self-reported ibromyalgia impact (FIQ) and increased quality of life (SF-36) scores from baseline. A 
similar result was obtained with the afective-emotional outcome variables. hat is, both groups showed a signif-
icant reduction in depressive symptoms and urinary cortisol levels at post-intervention.
Expectation of symptom improvement could be the primary factor underlying this “placebo efect”37. his 
efect has been widely demonstrated in the literature, even in people with FMS38. herefore, the present results 
indicate that probiotic treatment did not signiicantly improve depressive or anxiety symptoms when compared 
to the placebo group. As far as we know, this is the irst time that probiotics have been used with FMS patients 
to evaluate their impact on anxiety and mood. Previous studies have suggested the potential beneicial efects of 
probiotics as a preventive or adjuvant therapy for depression13,18,39. It is possible that in the case of people with 
physical and/or psychological impairments, probiotics themselves produce a beneicial efect on their emotional 
level (e.g., reducing anxiety and/or depression) when used as a therapeutic tool within a more comprehensive 
treatment framework, as suggested by Logan and Katzman18. his could be the case with FMS, where the symp-
toms of chronic, widespread and difuse pain are oten accompanied by stifness, fatigue, sleep disorder, reduced 
mental performance, depression and vulnerability to the efects of negative mood29–31,33,35–39. he clariication of 
this issue may be a task for future studies.
Questionnaires and Physiological outcomes
Pre-intervention Post-intervention
p-
valueaProbiotic Placebo Probiotic Placebo
VAS 6.69 (0.41) 7.50 (0.50) 5.49 (0.38) 6.05 (0.62) 0.72
FIQ 60.92 (2.90) 68.18 (4.63) 55.06 (4.61) 56.15 (5.20) 0.17
SF-36
  General Health 27.81 (3.19) 24.00 (4.09) 34.84 (4.00) 26.67 (5.49) 0.31
  Emotional Role 39.58 (12.25) 13.33 (7.13) 43.75 (11.27) 37.78 (12.54) 0.14
  Physical Function 39.27 (6.49) 32.33 (5.56) 50.63 (6.77) 42.33 (6.43) 0.78
  Physical Role 3.13 (2.13) 5.00 (5.00) 18.75 (8.39) 23.33 (8.61) 0.81
  Corporal Pain 23.44 (3.64) 18.33 (4.72) 32.97 (5.94) 30.67 (5.22) 0.75
  Vitality 24.06 (3.98) 13.33 (4.04) 31.88 (4.74) 25.67 (6.05) 0.43
  Social Function 36.72 (5.87) 32.50 (6.43) 46.88 (6.51) 47.50 (6.92) 0.51
Health Evolution 42.75 (3.61) 31.47 (5.15) 52.00 (4.68) 44.80 (6.02) 0.44
BDI 21.75 (2.10) 30.73 (3.33) 18.88 (2.20) 24.93 (4.07) 0.33
STAI
State 34.32 (1.53) 33.07 (0.94) 36.07 (3.25) 37.33 (3.79) 0.60
Trait 40.19 (2.87) 44.07 (3.05) 37.19 (2.91) 40.67 (3.59) 0.90
MMSE 28.50 (0.42) 28.47 (0.42) 28.44 (0.42) 28.73 (0.28) 0.50
Cortisol 2531.65 (88.51) 2664.86 (99.37) 1611.76 (70.73) 1802.15 (63.54) 0.70
Table 2. Mean scores and standard error of the means (shown in parentheses) on the questionnaires and 
physiological measures in the Probiotic and Placebo groups. p values indicate the Time by Group interaction. 
ap-values for Time by Group interaction from repeated measures ANOVAs.
Figure 1. Mean impulsive choices (IC; short-delay) on the two-choice task. Data are presented as the mean and 
standard error (error bars).
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When we considered the cognitive outcomes, response inhibition and decision-making, results showed a 
signiicant efect of probiotic treatment as compared to the placebo group. he probiotic group showed signif-
icantly fewer impulsive choices than the placebo group at post-intervention, whereas both groups had similar 
performance at baseline. To our knowledge, this is the irst intervention study to show a reduction of impulsive 
behaviour in FMS patients who received a probiotic formulation for 8 weeks. his inding is in agreement with 
the results of a preclinical study in mice, which showed a signiicant reduction of obsessive-compulsive symptoms 
ater probiotic treatment40.
Similar indings were obtained with the IGT, which assesses emotion-based decision-making. As shown in 
previous studies35, patients with FMS did not exhibit (either at baseline or post-intervention phase) the typical 
learning curve observed in healthy adults. Actually, the learning curve was lat in both the probiotic and placebo 
groups, which suggests a failure to learn how to optimise choices across the ive blocks. However, the placebo 
group showed a downward tendency in performance (more disadvantageous choices at the end of the task) at the 
post-intervention that was not present for any of the groups at the pre-treatment assessment phase. We suggest 
that this downward tendency for the placebo group relected an increase in the severity of impulsivity-related 
symptoms in FMS with the pass of time (two months elapsed from the pre- and post-intervention phases), which 
was ameliorated in the treatment group due to the efect of probiotic supplements. Future research should further 
investigate this hypothesis.
We also believe that the positive efect of probiotics in reducing impulsive behaviour in FMS patients may 
be explained in terms of the neuromodulatory efects of probiotics on serotonin and dopamine via the vagus 
nerve and the hypothalamus (see Collins and Bercik41, and Mayer et al.8, for reviews). Speciically, it has been 
demonstrated that probiotics can modulate the production and release of neuroactive substances such as GABA, 
serotonin, dopamine, acetylcholine and cytokines42. For instance, it has been found that some species of the genus 
Lactobacillus, even at nanomolar concentrations, trigger serotonin production in the central nervous system42. 
Similar results have been observed with some species of Lactobacillus in relation to dopamine production in the 
central nervous system43. Neuroanatomical evidence supports the role of the cortico-striatal-thalamic-cortical 
axis in impulsivity44,45, which has been particularly linked to alterations in serotonin and dopamine44–47. Future 
studies should be conducted to test the hypothesis that the positive efects of a probiotic treatment on impulsive 
behaviour might be mediated by monoaminergic alterations produced in the GBA.
he present study is not free from limitations. First, dietary measures and control for consumption of other 
fermented foods (e.g., yogurt) were not included. Hence, we cannot exclude that the consumption of probiotics 
was accompanied by spontaneous dietary changes that may have indirectly accounted for the observed efects. 
Second, the efect of the probiotic treatment in the microbiota was not conirmed (e.g., by stool bacterial anal-
ysis), although it should be noted that (i) previous studies have shown that the strains of probiotics included in 
the commercialised probiotics formula employed in the present study are able to restore the balance of the gut 
lora; and (ii) studies using partly the same bacterial strains as those used in the present study have conirmed 
the presence of such strains in stool samples of healthy volunteers48. herefore, we propose that further studies 
should control participant’s diet habits during treatment and measure the efect of probiotics on microbiota in a 
larger sample of patients to replicate and extend the present indings of a positive efect of probiotics on impulsive 
behaviour. Future studies might also manage the high placebo efect that we observed in some of the emotional 
measures by the recruitment of greater number of patients or more severely afected patients49.
To conclude, the present indings demonstrate, for the irst time, that an 8-week multispecies probiotic inter-
vention improves cognition, speciically impulsive choice and decision-making, in a group of patients diagnosed 
with FMS. No others beneicial efects were observed in self-reported pain, quality of life, ibromyalgia impact, 
depressive or anxiety symptoms. Future studies should investigate the efects of probiotics in combination with 
other treatments, including dietary changes, in FMS and other clinical populations, as well as the impact of 
Figure 2. Mean net scores earned on the Iowa gambling task (IGT) by blocks of trials (total number of cards 
picked from the advantageous decks minus the total number of cards picked from the disadvantageous decks). 
Data are presented as the mean and standard error (error bars). *p < 0.05 indicates statistical signiicance, 
compared to the placebo group.
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these live organisms on other cognitive functions afected in FMS patients (e.g., cognitive lexibility or working 
memory).

Ǥ his was a double-blind (group allocator, participants, outcome assessor) randomised con-
trolled intervention pilot study, with a placebo control group and an experimental group. he intervention study 
lasted for 8 weeks, from December 2015 to February 2016.
his study was part of a larger study50 that received ethics approval by the Human Research Ethics Committee 
of the University of Almeria (Spain). he intervention study was registered with ClinicalTrial.gov (NCT02642289; 
December 30, 2015). Here, we report the results from two cognitive tasks to evaluate impulsive choice and 
decision-making as well as those from mood and functional state self-report questionnaires in two groups of par-
ticipants (Probiotic 2 and control). Informed written consent, including information about the diferent types of 
intervention (probiotic vs. placebo), was obtained from all participants. his study was conducted in accordance 
with the Declaration of Helsinki and the Consolidated Standards of Reporting Trials (CONSORT) see electronic 
supplementary information.
Ǥ Forty patients diagnosed with FMS according to the criteria of the American College of 
Rheumatology (ARC)19,20 participated in the study. Fibromyalgia patients were recruited from the Almeria 
Fibromyalgia Association (AFIAL-Spain) or from El Ejido Fibromyalgia Association (AFIEL-Spain) and had 
been diagnosed at least 1 year before entering the study by a relevant clinician who in accordance to Wolfe et al.21 
employed both ACR criteria, from 1990 and 2010. Exclusion criteria included: (1) using antibiotics and nutri-
tional supplements, (2) allergies, (3) currently participating in other psychological or medical studies, (4) being 
pregnant or breastfeeding, (5) severe intestinal disease, and (6) meeting the criteria for psychiatric disorders other 
than depression and/or anxiety. An initial telephone or personal interview was conducted to ensure that the par-
ticipants fulilled the basic study criteria. A total of 60 people were assessed for eligibility; 8 refused to participate, 
and 12 were excluded because they did not meet the inclusion criteria (see Fig. 3).
Each participant was randomly assigned to either the placebo or the intervention (probiotic) group through a 
random number generator. Twenty participants (1 male) with a mean age of 55.00 ± 8.37 years and a mean body 
mass index (BMI) of 29.4 ± 6.57 kg/m2 were assigned to the probiotic condition, and 20 participants (2 males) 
with a mean age of 50.27 ± 7.86 years and a mean BMI of 30.23 ± 6.31 kg/m2 were assigned to the placebo condi-
tion. During the 8 weeks, four participants in the probiotic group abandoned the study (two of them due to intes-
tinal discomfort, and the other two for reasons unrelated to the intervention), and ive participants in the placebo 
Figure 3. Summary of patient low diagram according to Consort’s requirement. *See “Statistical analyses” for 
more details about analysed participants in each group.
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group abandoned the study due to non-adherence to treatment. hus, the inal sample included 16 participants in 
the probiotic condition and 15 participants in the placebo condition (see Fig. 3).
Ǥ In the probiotic intervention group, participants were given four bottles, without identiication, 
of ERGYPHILUS Plus (Laboratorios NUTERGIA S.L., Spain) containing 60 pills each (6 million reviviication of 
germs per capsule). ERGYPHILUS Plus contains the following bacterial strains: Lactobacillus Rhamnosus GG®, 
Casei, Acidophilus, and Biidobacterium Biidus. In the placebo intervention group, participants were also given 
the same four bottles containing 60 pills each; the pills (composed of cellulose) were indistinguishable from the 
probiotics in colour, taste and smell (provided by Complementos Fitonutricionales –CFN- S.L., Spain).
All participants were evaluated pre- (baseline) and post-intervention, for pain, impact of ibromyalgia, anxiety, 
depressive symptoms and quality of life. heir performance in two impulsivity tasks was also assessed. Finally, 
pre- and post-treatment urine free cortisol levels were measured using a irst urine sample collected in a sterile 
container and conserved at −20 °C. Each participant was instructed to refrain from ingesting medication which 
they could stop without signiicant health consequences and that could afect cognitive performance (for exam-
ple, opioid analgesics) at least 48 h before the assessment, and from 3 hours prior to the assessment any CNS 
stimulant or depressant (for example, alcohol, tobacco and cofee).
A week ater the pre-intervention assessment, participants were given two bottles (containing either the inert 
placebo or the multispecies probiotic) for the irst 4-week intervention. hree weeks later, they were given the 
other two bottles for the rest of the intervention. Participants (both placebo and probiotic) received detailed dos-
ing schedule instructions. hey were required to take two pills at least 30 minutes before breakfast and two pills at 
least 30 minutes before dinner. hey were also instructed to store the bottles in the refrigerator.
Ǥ Demographic and questionnaires. All participants provided the following demo-
graphic and clinical information: gender, age, FMS diagnosis onset, years of formal education and body mass 
index (BMI) that was calculated by dividing the weight (in kilograms) by the square of height (in meters).
Pain was assessed with the Visual Analogue Scale (VAS)51, a widely used unidimensional measure of pain 
intensity. he score ranges from 0 (no pain) to 10 (worst imaginable pain). he VAS has shown an internal con-
sistency of 0.56 to 0.8852.
he impact of ibromyalgia was measured by the Fibromyalgia Impact Questionnaire (FIQ; Burckhardt et al.53; 
Spanish version by Monterde et al.54), a self-administered questionnaire that consists of 21 individual questions 
that assess perceived pain intensity in the context of the past 7 days. Each question is answered using a Likert-like 
scale from 0 to 10. he FIQ total score ranges from 0 to 100, with higher scores indicating greater impact of the 
condition on the person’s life55.
he SF-36 Quality of Life Questionnaire (Ware and Sherbourne56; Spanish version by Alonso et al.57) was 
employed to measure participants’ quality of life. he questionnaire consists of 36 items grouped into eight 
domains: physical, social, emotional, mental health, vitality, overall health, and changes in health over time. 
Scores for each sub-domain range from 0 (worst health status) to 100 (optimal health status). Studies have 
reported good internal consistency for the SF-36, the α coeicient ranges from 0.78 to 0.9657.
Anxiety levels were measured with the 40-item State-Trait Anxiety Inventory (STAI; Spielberger et al.58; 
Spanish version by Seisdedos59), which measures state and trait anxiety separately. Participants are asked to report 
the intensity and frequency of their feeling of anxiety using a Likert-like scale from 0 (not at all for intensity, 
and almost never for frequency) to 4 (very much so for intensity and almost always for frequency). Studies have 
reported good internal consistency for the two scales, α coeicient from 0.90 to 0.93 for the STAI-state and from 
0.84 to 0.91 for the STAI- trait58.
he presence and severity of depressive symptoms were measured with the Beck Depression Inventory (BDI; 
Beck et al.60; Spanish version by Conde and Useros61). his is a self-reported questionnaire that consists of 21 
items that assess the intensity of depressive symptoms using a Likert-like scale from 0 (symptom not present) to 
3 (symptom very intensive)62. he total score ranges from 0 to 63, with higher scores indicating higher levels of 
depression. he test-retest reliability of the BDI is good (r ranges from 0.65 to 0.72) and so is the internal consist-
ency (α = 0.82)63.
Participants also completed the adapted and validated Spanish version of the Mini-Mental State Examination 
(MMSE)64, a screening measure of global cognitive function. he score ranges from 0 to 30, with a cut-of score 
of 24 for potential dementia diagnosis.
Cognitive tasks. Participants performed two computerised cognitive tasks widely used to assess impulsive 
choice and decision-making; the two-choice task and the Iowa gambling task, respectively. E-Prime 2.0 sotware 
(Psychology Sotware Tools, Pittsburgh, PA) controlled the presentation of the stimuli as well as collection of the 
participant’s responses in the tasks. Stimuli were presented on a dark background on a colour monitor (VGA) of 
an IBM/PC compatible computer.
he two-choice task measures the tendency to choose a small reward over a larger delayed reward65. In this 
study, participants were presented with 40 trials in which they could choose to wait 5 s for ive points or 15 s for 
iteen points. On each trial, a diamond and a star appeared on the screen. Participants were required to select one 
of the two shapes. he length of the delay and the size of the reward associated with each shape remained constant 
across the testing session; for example, the star allowed the participant to earn 5 points ater waiting 5 s, while the 
diamond was followed by 15 points ater waiting for 15 s. Impulsive choices were deined as the total number of 
short-delay reward responses.
A computerised version of the original Iowa gambling task (IGT; Bechara et al.66) was used as a measure 
of impulsive decision-making. his task measures risk sensitivity, as deined by the inability to anticipate and 
relect on the consequences of decision-making. Participants made a total of 100 card selections from four decks 
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of cards labelled A, B, C and D. hey were instructed to select one card, with the goal of obtaining the highest 
amount of virtual money. Decks A and B produced higher returns than C and D, but also greater losses, so the net 
result is earning less virtual money. hus, options A and B are disadvantageous, while C and D are advantageous. 
he analysis is conducted by grouping the 100 trials of the task into blocks of 20 trials each and calculating an 
IGT-index for each block by the following formula: (C + D) − (A + B).
Physiological measures. Urine samples were tested for their concentration of cortisol using a competitive ELISA 
kit (RE5224, Cortisol ELISA, IBL International, Hamburg, Germany) with a DU 530 Beckman spectrophotome-
ter. he ELISA kit is a competitive immunoenzymatic colorimetric method for quantitative determination of free 
cortisol concentration in urine. he lowest detectable concentration of urinary cortisol that can be distinguished 
from the zero standard is 2.0 ng/mL at the 95% conidence limit, according to the manufacturer. he assay was 
performed according to the instructions and the procedure provided by the manufacturer.
Ǥ Statistical analyses and graphics were performed using SPSS v19.0 (SPSS, Inc., Chicago, IL) 
and GraphPad Prism v7.0 (GraphPad Sotware, La Jolla California USA), respectively. All alpha levels were set at 
p < 0.05. As this was a pilot study, no power analysis was performed to pre-determine sample size.
First, a descriptive analysis was performed and the normal distribution of variables was verified by the 
Kolgomorov-Smirnov test. Baseline demographics were compared between both groups using χ2 tests for cate-
gorical data and Student t-tests for continuous data. For questionnaires and behavioural measurement of impul-
sivity, the mean scores (total and/or partial) were submitted to a repeated measures analysis of variance (ANOVA) 
with Time (pre- vs. post-intervention) as the within-subjects factor and Group (probiotic vs. placebo) as the 
between-subjects factor. In addition to the statistical signiicance levels, the efect size estimates were calculated by 
ηp2 (partial eta-squared). his indicator provided estimates of the magnitude of the efects that are independent 
of the sample size67,68.
Due to technical problems, four participants assigned to the probiotic group and four participants assigned 
to the placebo group were missing in the IGT as well as ive participants from the placebo group and three from 
the probiotic group in the two-choice task. Data from one participant assigned to the probiotic group were also 
deleted from the cortisol measure. No other data were missing.
All data analysed during the current study are available from the corresponding author on reasonable request.
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